News

  1. Details of hotspots seen by STORM
    New article from the NeuroCyto Team: Slow axonal transport of actin via hotspots and trails

    The latest work of the NeuroCyto Team (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab to reveal a new mechanism of slow axonal transport, based on the previous discovery of actin hotspots and trails. Hotspots are static actin clusters that appear and disappear within minutes every 3-4 µm along the axon. They generate the assembly of trails, long actin filaments that polymerize along the axon and collapse within seconds.

  2. The INP welcomes Professor Emeritus Jean-Michel SCHERRMANN

    On Friday, November 23, the INP welcomes Professor Emeritus Jean-Michel SCHERRMANN (University of Paris Descartes), for a seminar entitled "Why it is difficult to develop CNS drugs: lack of neuropharmacokinetic considerations?”

    The conference will take place, from 10am to 11am, in the Pastor amphitheatre, within the Faculty of Pharmacy.

  3. 1st Congress of the 7 CoENs (International Network of Centers of Excellence in Neurodegeneration)

    On October 18 and 19, 2018, the 1st Congress of the 7 CoENs (International Neetwork of Centers of Excellence in Neurodegeneration) was held in Montpellier, endorsed by AVIESAN: Bordeaux, Grenoble, Lille, Montpellier, Marseille, Paris and Toulouse. The purpose of the CoEN European Program is to build a transnational collaborative research space in Europe that enables synergies between science, clinical research and human sciences. For two days, teams representing these disciplines presented their work and could exchange in a friendly and inspiring environment.

  4. Ludovic Leloup (team cytoskeleton & neurophysiopathology) received a 30 000 € grant from the GEFLUC

    The Emergence project entitled “Tau, from Alzheimer disease to glioblastoma, evolution of a prognostic marker” was selected by the Canceropole PACA to be founded by the GEFLUC (groupement des entreprises françaises dans la lutte contre le cancer). Team 9 has a long-time expertise on Tau and this grant will be used to complete the identification of the kinases responsible for Tau phosphorylation in glioblastoma.

    Photo from the GEFLUC

  5. NeuroSchool: a School of Neuroscience for and by AMU students

    On September 12, over 300 students, teachers, researchers, clinicians and entrepreneurs participated in the launch of NeuroSchool, the school that unifies and harmonizes the teachings of the third year of the bachelor's degree (Neuroscience path), the master's degree and the PhD program in neuroscience. Funded by the National Research Agency and the A*Midex Foundation, NeuroSchool will benefit from a funding of approximately 10 million euros (over 10 years).

  6. Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED participated in the ECMED EU-GliaPhD international conference organized in Malta

    Michel Khrestchatisky gave a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.       

  7. François Devred gave one of the 38 selected talks in EUROTAU 2018

    #EUROTAU 2018 - European scientists involved in Tau research met in Lille to exchange new ideas and hypotheses on physiological and pathological roles of tau proteins (26-27th April 2018). François Devred gave one of the 38 selected talks in which he presented a new reversible oligomerization of tau protein evidenced in INP team 9, which could have a protective physiological role and prevent pathological aggregation of tau in neurodegenerative diseases. Next edition of EuroTau will be in 2020.

    Photo © Valérie Buée Scherrer

  8. The Viewpoint article by C. Leterrier was selected for the cover image of The Journal of Neuroscience , 2018 February 28 issue

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

New article from the NeuroCyto Team: Slow axonal transport of actin via hotspots and trails

The latest work of the NeuroCyto Team (previously on bioRxiv) is now published in the Journal of Cell Biology. We collaborated with the Roy lab to reveal a new mechanism of slow axonal transport, based on the previous discovery of actin hotspots and trails. Hotspots are static actin clusters that appear and disappear within minutes every 3-4 µm along the axon.

Undefined
Details of hotspots seen by STORM

1st Congress of the 7 CoENs (International Network of Centers of Excellence in Neurodegeneration)

On October 18 and 19, 2018, the 1st Congress of the 7 CoENs (International Neetwork of Centers of Excellence in Neurodegeneration) was held in Montpellier, endorsed by AVIESAN: Bordeaux, Grenoble, Lille, Montpellier, Marseille, Paris and Toulouse. The purpose of the CoEN European Program is to build a transnational collaborative research space in Europe that enables synergies between science, clinical research and human sciences. For two days, teams representing these disciplines presented their work and could exchange in a friendly and inspiring environment.

Undefined

Ludovic Leloup (team cytoskeleton & neurophysiopathology) received a 30 000 € grant from the GEFLUC

The Emergence project entitled “Tau, from Alzheimer disease to glioblastoma, evolution of a prognostic marker” was selected by the Canceropole PACA to be founded by the GEFLUC (groupement des entreprises françaises dans la lutte contre le cancer). Team 9 has a long-time expertise on Tau and this grant will be used to complete the identification of the kinases responsible for Tau phosphorylation in glioblastoma.

Photo from the GEFLUC

Undefined

NeuroSchool: a School of Neuroscience for and by AMU students

On September 12, over 300 students, teachers, researchers, clinicians and entrepreneurs participated in the launch of NeuroSchool, the school that unifies and harmonizes the teachings of the third year of the bachelor's degree (Neuroscience path), the master's degree and the PhD program in neuroscience. Funded by the National Research Agency and the A*Midex Foundation, NeuroSchool will benefit from a funding of approximately 10 million euros (over 10 years).

Undefined

Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED participated in the ECMED EU-GliaPhD international conference organized in Malta

Michel Khrestchatisky gave a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.       

Undefined

François Devred gave one of the 38 selected talks in EUROTAU 2018

#EUROTAU 2018 - European scientists involved in Tau research met in Lille to exchange new ideas and hypotheses on physiological and pathological roles of tau proteins (26-27th April 2018). François Devred gave one of the 38 selected talks in which he presented a new reversible oligomerization of tau protein evidenced in INP team 9, which could have a protective physiological role and prevent pathological aggregation of tau in neurodegenerative diseases. Next edition of EuroTau will be in 2020.

Photo © Valérie Buée Scherrer

Undefined

Next seminars

23 Nov 2018 10:00

Jean-Michel Scherrmann - "Why it is difficult to develop CNS drugs: lack of neuropharmacokinetic considerations?”

Faculté de pharmacie de la Timone, Amphithéatre Pastor, RdC

Jean-Michel SCHERRMANN, Emeritus professor, Faculté de Pharmacie de Paris, INSERM U1144, Université Paris Descartes

Jean-Michel Scherrmann, Pharm. D., Ph. D. is professor in the department of Pharmacokinetics, Faculty of Pharmacy, University Paris Descartes. He received his Pharm.D. and Ph. D. in analytical radiochemistry. He has led the Neuropsychopharmacology Unit at Inserm.

 

ABSTRACT :

Why it is difficult to develop CNS drugs: lack of neuropharmacokinetic considerations?

The research and development of CNS drugs are characterized by a high attrition rate. One of the main reasons is often related to the restrictive permeability of the blood-brain barrier, which is the main interface between the brain and the blood systemic circulation.

During the presentation, I will demonstrate that crossing the brain barriers is not the only event explaining failures in developing CNS drugs. Distribution of drug candidates within the brain parenchyma can represent another obstacle as well as clearance processes aiming to eliminate compounds from the brain tissue. These processes are different according to the type of drug candidate, i.e., small chemicals versus biologics. Several CNS drug examples will illustrate that the trilogy:  brain penetration-distribution and elimination should be better considered for developing brain therapies with small molecules or biologics.

23 Nov 2018 11:00

Jean-Michel Paumier - "Métalloprotéases matricielles et maladie d'Alzheimer : étude des rôles de MT1- et MT5-MMP dans l'amyloïdogenèse et la neuro-inflammation"

Faculté de pharmacie de la Timone, Amphithéatre Pastor, RdC

Rehearsal of Jean-Michel Paumier's thesis defense, PhD student of the team 1 - Neural Plasticity and Degeneration.

30 Nov 2018 14:30

Fanny Gaudel - "Caractérisation des chimiorécepteurs dans le cerveau"

Faculté de médecine Nord, salle de conférences, bâtiment E

Rehearsal of Fanny Gaudel's thesis defense, PhD student of the team 2 - Genes, Rhythm and Neurophysiopathology.

14 Dec 2018 14:30

Pauline Rontani (Team 2 - Genes, Rhythm and Neurophysiopathology)

Faculté de pharmacie de la Timone, Salle TD5 BC (Sous sol, Aile B)

Rehearsal of Pauline Rontani's thesis defense, PhD student of the team 2 - Genes, Rhythm and Neurophysiopathology.

Partners